Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate

Cancer Letters

Volumn 148, Issue 2, 2000, Pages 189-195

  Boratyński, Janusz ^a   Opolski, Adam ^a   Wietrzyk, Joanna ^a   Górski, Andrzej ^a   Radzikowski, Czeslaw ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Cancer; Conjugate; Drug carriers; Fibrinogen; Methotrexate

Indexed keywords

DRUG CARRIER; FIBRINOGEN; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFECT; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; FIBRINOGEN; HUMANS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAPERITONEAL; LEUKEMIA P388; MALE; METHOTREXATE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; SOLUBILITY; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0343049111     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00334-1     Document Type: Article

References (33)

1. Boratyński J., Syper L. The cytotoxic activity of heterologous anti L-1210 antibodies conjugated with quinones. Arch. Immunol. Ther. Exp. 31:1983;91-106.
2. Paprocka M., Boratyński J., Duś D., Kuśnierczyk H., Radzikowski C. Conjugation of the monoclonal antibody 17-1A with the nitroacridine compound C921 with poly-L-lysine as an intermediate agent. Arch. Immunol. Ther. Exp. 45:1997;343-349.
3. Smith G.K., Banks S., Blumenkopf T.A., Cory M., Humphreys J., Leathem R.M., Miller J., Moxham C.P., Mullin R., Ray P.H., Walton L.M., Wolfe L.A. Toward antibody-directed enzyme prodrug therapy with T268G mutant carboxypeptidase A1 and novel in vivo stabile prodrugs of methotrexate. J. Biol. Chem. 272:1997;15804-15816.
4. Wiedlocha A., Salwa J., Paprocka M., Steuden J., Radzikowski C. Specific killing of mouse leukemic cells with ricin A-chain immunotoxin. Arch. Immunol. Ther. Exp. 37:1989;101-113.
5. Vincze B., Palyi I., Gaal D., Pato J., Mora M., Mezo I., Teplan I., Seprodi J. In vivo studies of the new gonadotropin-releasing hormone antagonist-copolymer conjugates having antitumor activity. Cancer Detect. Prev. 20:1996;153-159.
6. Mehta S.C., Lu D.R. Targeted drug delivery for boron neutron capture therapy. Pharm. Res. 13:1996;344-351.
7. Lasic D.D. Doxorubicin in sterically stabilized liposomes. Nature. 380:1996;561-562.
8. Boratyński J., Zal T. Colorimetric micromethods for glutaraldehyde determination by means of phenol and sulfuric acid or phenol and perchloric acid. Anal. Biochem. 184:1990;259-262.
9. Boratyński J., Roy R. High temperature conjugation of proteins with carbohydrates. Glycoconjugate J. 15:1998;131-138.
10. Boratyński J. Dry reaction carbohydrates with proteins 120° yields neoglycoconjugates. Biotechnol. Techniques. 12:1998;705-711.
11. Harding N.G.L. Amethopterin linked covalently to water soluble macromolecules. Ann. N. Y. Acad. Sci. 186:1971;270-283.
12. Hudecz F. Design of synthetic branched-chain polypeptides as carriers for bioactive molecules. Anticancer Res. 6:1995;171-193.
13. Dang W., Colvin O.M., Brem H., Saltzman W.M. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. Cancer Res. 54:1994;1729-1735.
14. Hartung G., Stehle G., Sinn H., Wunder A., Schrenk H.H., Heeger S., Kranzle M. Phase I trial of methotrexate-albumin in weekly intravenous bolus regimen in cancer patients. Phase I Study Group of Association for Medical Oncology of the German Cancer Society. Clin. Cancer Res. 5:1999;753-759.
15. Ghose T.I., Blair A.H., Karlovec J., Mammen M., Uadia P.O. Rodwell J.D. Antibody-Mediated Delivery System. 1988;81 Marcel Dekker, New York.
16. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 43:1985;175-203.
17. Dvorak H.F., Senger D.R., Dvorak A.M. Fibrin as a component of the tumor stroma: origins and significance. Cancer Metast. Rev. 2:1983;41-73.
18. Nagy J.A., Brown L.F., Senger D.R., Lanir N., Van De Water L., Dvorak A.M., Dvorak H.F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta. 948:1988;305-329.
19. Dvorak H.F., Nagy J.A., Berse B., Brown L.F., Yeo K.-T., Yeo T.-K., Dvorak M., Van De Water L., Siousat T.M., Senger D.R. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann. N. Y. Acad. Sci. 667:1992;101-111.
20. Idell S., Pueblitz S., Emri S., Gungen Y., Gray L., Kumar A., Holiday D., Koenig K.B., Johnson A.R. Regulation of fibrin deposition by malignant mesothelioma. Am. J. Pathol. 147:1995;1318-1329.
21. Donati M.B. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb. Haemost. 74:1995;278-281.
22. Fujii K., Imamura S. RGD-sensitive melanoma cell adhesion on fibrinogen and vitronectin. Exp. Cell Res. 220:1995;201-211.
23. Hirakawa W., Kadota K., Asakura T., Niiro M., Yokoyama S., Hirano H., Yatsushiro K., Kubota Y., Shimodozono Y. Local chemotherapy for malignant brain tumors using methotrexate-containing fibrin glue. Gan. To. Kagaku. Ryoho. 22:1995;805-809.
24. Slavikova V., Dyr J.E., Motyčka K., Přistupilova K., Holy P., Slavík K. Organ distribution of fibrinogen-bound methotrexate in mice with Gardner lymphosarcoma. Neoplasma. 34:1987;269-275.
25. Motyčka K., Dyr J.E., Macáková A., Slavík K. Effect of free and bovine fibrinogen-bound methotrexate and dibromoaminopterin on the dissemination of solid Gardner lymphosarcoma. Neoplasma. 29:1982;197-204.
26. Dyr J.E., Hermanowa E., Slavík K., Vodražka Z. The effect of fibrinogen-methotrexate derivatives on HeLa cell growth. Neoplasma. 33:1986;401-407.
27. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyol M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
28. Experimental Therapeutics Program. In Vivo Cancer Models, 1976-1982. Bethesda, MD: NIH Publication No. 84-2635.
29. Khleif S.N., Curt G.A. Animal models in drug development. Holland J.F., Frei III E., Bast R.C. Jr., Kufe D.W., Morton D.L., Weichselbaum R.R. Cancer Medicine. 1993;653-666 Lea & Febiger, Philadelphia, London.
30. Manabe Y., Tsubota T., Haruta Y., Kataoka K., Okazaki M., Haisa S., Nakamura K., Kimura I. Production of a monoclonal antibody-methotrexate conjugate utilizing dextran T-40 and its biological activity. J. Lab. Clin. Med. 104:1984;445-454.
31. Endo N., Takeda Y., Umemoto N, Kishida K., Watanabe K., Saito M., Kato Y., Hara T. Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates. Cancer Res. 48:1988;3330-3335.
32. Hudecz F., Garnett M.C., Khan T., Baldwin R.W. The influence of synthetic conditions on the stability of methotrexate-monoclonal antibody conjugates determined by reversed phase high performance liquid chromatography. Biomed. Chromatogr. 6:1992;128-132.
33. Costantini V., Zacharski L.R. The role of fibrin in tumor metastasis. Cancer Metastasis Rev. 11:1992;283-290.